Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 7/20 | 0.38 |
| ▸ | JAK1 | P23458 | 7/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 3/20 | 0.37 |
| ▸ | TNKS | O95271 | 2/20 | 0.37 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.37 |
| ▸ | ACACB | O00763 | 2/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | KIT | P10721 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 2/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3489463 | 0.89 | JAK2 (0.40) | JAK2JAK1HDAC2HDAC1PARP1 | |
| SCHEMBL3489912 | 0.85 | JAK2 (0.40) | JAK2JAK1HDAC2HDAC1PARP1 | |
| SCHEMBL3489360 | 0.84 | JAK2 (0.42) | JAK2JAK1PARP1ACACBKIT | |
| SCHEMBL3489950 | 0.83 | BACE1 (0.44) | JAK2JAK1HDAC2HDAC1NAMPT | |
| SCHEMBL3489548 | 0.83 | NAMPT (0.38) | JAK2JAK1HDAC2HDAC1PARP1 | |
| SCHEMBL3491957 | 0.81 | SSTR4 (0.45) | NAMPT | |
| SCHEMBL3490376 | 0.81 | BCHE (0.45) | PARP1GPR119KITNAMPTCYP11B2 | |
| SCHEMBL3490328 | 0.80 | BACE1 (0.44) | ACACBNAMPT | |
| SCHEMBL3489471 | 0.78 | NAMPT (0.49) | JAK2JAK1ACACBGPR119KIT | |
| SCHEMBL3491078 | 0.77 | STS (0.42) | NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093748-A1 | SUBSTITUTED PIPERIDINES HAVING PROTEIN KINASE INHIBITING ACTIVITY | ASTEX THERAPEUTICS LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| US-20100093748-A1 | SUBSTITUTED PIPERIDINES HAVING PROTEIN KINASE INHIBITING ACTIVITY | ASTEX THERAPEUTICS LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| US-20100093748-A1 | SUBSTITUTED PIPERIDINES HAVING PROTEIN KINASE INHIBITING ACTIVITY | ASTEX THERAPEUTICS LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093748-A1 | SUBSTITUTED PIPERIDINES HAVING PROTEIN KINASE INHIBITING ACTIVITY | PRKAR2B, GRK3, PRKAR2A | JAK2 258/4885JAK1 284/4885HDAC2 1392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.